“If you have macular degeneration, or know someone who does, this is the place for you. There is hope and help.”
The Eyedaptic Solution – Why We Win

... effective full field of vision

... wearable for mobility

... easy to use & visually adaptive

... AR seamless integration

We simulate natural vision to help people return to fuller lives

U.S. FDA Class I Exempt Device
Magnification Alone is Inadequate

Current Low Vision Aids Offering ONLY Magnification, Color and Contrast Adjustments Not Addressing Advanced AMD Sufferers’ Needs

Initial Target: Late Stage AMD 10M worldwide

178M AMD sufferers worldwide

400M with retinal disease worldwide

NO Available Treatment for Dry AMD (90% of cases)

It Drastically Diminishes Field of Vision

Market Landscape
Why We Uniquely Help Users

We provide the whole picture by both maintaining a Wide Field of View and recovering the Central Field.

Eyedaptic effectively reconstructs the visual field!
How Our Solution Works

Simulated Natural Vision

Open Market AR Hardware + Proprietary Software

1. 7 Patents pending (+9 Provisionals filed) & FTO completed

Vision w/AMD

Image Capture

Display

Adaptive Systems

Simulated Natural Vision
How Our Solution Works – “Hybrid see-through”

**Virtual Reality (Video see-through)**
- Isolated from reality
- Complete loss of peripheral vision

**Augmented Reality (Optical see-through)**
- Double image hard for Low Vision
- Abrupt demarcation w/ reality

**Eyedaptic – Hybrid see-through**
- Full peripheral vision & connected to reality
- Reality integrated w/image & blended w/SW

---

1. Provisional & Patent Pending for Hybrid See Through
Technology Validation & Clinical Trials

35 Users to Date
73 – 105 Age Range
20/60 – 20/400 Vision
Mostly Dry AMD

Technology validated
improved reading
&
everyday tasks easier

EYE-01 @ 3X (n=15)
Improved 33% - 50%

Bill  Cans  Signs

Rx Only  Portal  Britext
Assessment of ability to perform a given task with and without EYE-01

**Timed Independent Activities of Daily Living (TIADLs):**
- Reading a bill
- Identify & Read Cans
- Sign spotting & reading

**Successful Task Completion**

- Bill: Over 6X Improvement
- Cans: Over 6X Improvement
- Signs: Over 6X Improvement
In Home Usage – Profile (74M→20/200 Programmer)

Goal: Assess In Home Useability & UI/UX Robustness → Reading Tasks

>3 months of data shows increased usage in both frequency & duration

Session length also increasing with 14 days used >3-6 hours/day
In Home Usage – User 2 (91M→20/70 WWII Vet)

Goal: Profile combination usage with mobility → Supermarket
In Home Usage – User 3 (16F→20/400 HS Student)

Goal: Profile combination usage with mobility → New Year’s Eve Party
Team

Technology

Dr. Mitul Mehta
Chief Medical Officer
Cofounder

Dr. B. Kuppermann
Retina Advisor

Dr. Becky Kammer
Low Vision Advisor

Dr. Brian Kim
Medical Advisor
Cofounder

Peter Gluck Esq.
IP Advisor &
Patent Council

Dr. Paul Karpecki
Optometry Advisor

Jay Cormier
President & CEO
Founder

Dave Watola
Chief Tech Officer
Cofounder

Jerry Fitch
Board Director

Art Reidel
Board Director

Orlando Rodrigues
Eye Care Ecosystem
Commercial Advisor

Jim Cobb
Medical Device
Commercial Advisor

Medical

Dr. Mitul Mehta
Chief Medical Officer
Cofounder

Dr. B. Kuppermann
Retina Advisor

Dr. Becky Kammer
Low Vision Advisor

Dr. Brian Kim
Medical Advisor
Cofounder

Peter Gluck Esq.
IP Advisor &
Patent Council

Dr. Paul Karpecki
Optometry Advisor

Jay Cormier
President & CEO
Founder

Dave Watola
Chief Tech Officer
Cofounder

Jerry Fitch
Board Director

Art Reidel
Board Director

Orlando Rodrigues
Eye Care Ecosystem
Commercial Advisor

Jim Cobb
Medical Device
Commercial Advisor

Synergy
Key Milestones

- **2017**: $725K raised
- **2018**: Completed 2018
- **2019**: $1.4M raise Launch Capital

- Protos & Core Tech Validated
- Patents Filed
- Preclinical Data
- EYE1.1 Study Data
- Team Formed
- UI Testing
- Clinical Trial
- Beta Testing
- USA Launch

- Eyedaptic